Multiple Myeloma - A New Era of Treatment Strategies

Indexed in: Book Citation Index, Science Edition (BKCI-S), Web of Science, Scopus, EBSCO.

Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

A Short History of Multiple Myeloma

Pp. 3-14 (12)

DOI: 10.2174/978160805297411201010003

Author(s): Robert A. Kyle, David P. Steensma


Although multiple myeloma has probably been present for centuries, the first welldocumented case was published less than 160 years ago. The famous patient, Thomas Alexander McBean excreted large amounts of a peculiar protein that was studied by Henry Bence Jones. Jones was a well-recognized physician as well as chemist. Less than a half-century ago, Bence Jones protein was found to consist of monoclonal light chains. Otto Kahler described a patient with autopsy-proven multiple myeloma; this patient survived eight years after the onset of symptoms despite the absence of effective therapy. The discovery of Roentgen’s rays facilitated the diagnosis of multiple myeloma. Serum electrophoresis followed by immunofixation allowed physicians to readily make the diagnosis. Melphalan was introduced for therapy half a century ago but little progress was made until autologous stem cell transplantation became available almost 20 years ago. This was followed by the introduction of the “novel” agents thalidomide, bortezomib and lenalidomide in the last decade.


Bence Jones protein, Kahler’s disease, plasma cell, multiple myeloma, immuno/electrophoresis, immunofixation, angiogenesis, urethane, Melphalan, prednisone, stem cell transplantation, thalidomide, lenalidomide.